Acute myeloid leukaemia (AML) is a disease with high intra- and interpatient heterogeneity. Current treatments are still based on cytarabine combined with an anthracycline, with 5-year overall survival rates below 30%. Functionalist oncology utilises edge-weig... ...

请注册登录后继续浏览